{"protocolSection":{"identificationModule":{"nctId":"NCT02549963","orgStudyIdInfo":{"id":"GDCI 201501"},"organization":{"fullName":"Guangdong Provincial People's Hospital","class":"OTHER"},"briefTitle":"Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban","officialTitle":"A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation"},"statusModule":{"statusVerifiedDate":"2015-09","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-10"},"primaryCompletionDateStruct":{"date":"2017-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-09-08","studyFirstSubmitQcDate":"2015-09-13","studyFirstPostDateStruct":{"date":"2015-09-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-09-23","lastUpdatePostDateStruct":{"date":"2015-09-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Shulin Wu","investigatorTitle":"Director of Guangdong Cardiovascular Institute","investigatorAffiliation":"Guangdong Provincial People's Hospital"},"leadSponsor":{"name":"Shulin Wu","class":"OTHER"},"collaborators":[{"name":"Wuhan Asia Heart Hospital","class":"OTHER"},{"name":"Beijing Anzhen Hospital","class":"OTHER"},{"name":"First Affiliated Hospital, Sun Yat-Sen University","class":"OTHER"},{"name":"Second Affiliated Hospital of Guangzhou Medical University","class":"OTHER"},{"name":"The First Affiliated Hospital of Guangzhou Medical University","class":"OTHER"},{"name":"Guangdong Medical College","class":"OTHER"},{"name":"First Affiliated Hospital of Jinan University","class":"OTHER"},{"name":"Nanfang Hospital, Southern Medical University","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a prospective, multi-center, randomized, pilot study comparing the WATCHMAN left atrial appendage occlusion device with Rivaroxaban therapy in patients with non-valvular atrial fibrillation."},"conditionsModule":{"conditions":["Atrial Fibrillation","Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":200,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"WATCHMAN LAA Occlusion Device","type":"EXPERIMENTAL","description":"Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.","interventionNames":["Device: WATCHMAN Left Atrial Appendage Occlusion Device"]},{"label":"Rivaroxaban","type":"ACTIVE_COMPARATOR","description":"Subjects assigned to receive the Rivaroxaban therapy.","interventionNames":["Drug: Rivaroxaban"]}],"interventions":[{"type":"DEVICE","name":"WATCHMAN Left Atrial Appendage Occlusion Device","armGroupLabels":["WATCHMAN LAA Occlusion Device"],"otherNames":["WATCHMAN Left Atrial Appendage Closure"]},{"type":"DRUG","name":"Rivaroxaban","armGroupLabels":["Rivaroxaban"],"otherNames":["Novel Oral Anticoagulant"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Combined endpoint","description":"All Stroke or Systemic embolism or Cardiovascular death","timeFrame":"2 year"}],"secondaryOutcomes":[{"measure":"All bleeding event","description":"Any bleeding with a need for hospitalization, instrumental procedure or discontinuation of anticoagulation or antithrombotic treatment.","timeFrame":"2 year"},{"measure":"Major bleeding event","description":"An overt bleeding accompanied by one or more of the following: a decrease in hemoglobin level of 20 g/l or more over a 24-hour period, transfusion of 2 or more units of packed red cells, bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intramuscular with compartment syndrome, or retroperitoneal), or fatal bleeding","timeFrame":"2 year"},{"measure":"Technical and procedure related event","description":"A pericardial effusion with a need for drainage, surgical or pericardiocentesis, or cardioembolic event during the procedure, or significant periprocedural bleeding (i.e. major vascular bleeding with a need for surgical revision, or blood concentrate transfusion), or device embolization, or thrombus of the device with a consequent cardioembolic event.","timeFrame":"45 days"},{"measure":"Cognitive function change","description":"Montreal Cognitive Assessment(MoCA) will be performed to detect cognitive function change.The differences between the MoCA test score in WATCHMAN group and in a control group of Rivaroxaban","timeFrame":"2 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Paroxysmal, persistent or permanent non-valvular atrial fibrillation\n* Eligible for LAAO and long-term rivaroxaban therapy\n* Calculated CHA2DS2-VASc score of 2 or greater.\n\nExclusion Criteria:\n\n* Contraindicated/allergic to aspirin, clopidogrel and novel oral anticoagulants.\n* Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment.\n* History of atrial septal repair or has an atrial septal defect/patent foramen ovale device.\n* History of valvular heart disease.\n* Implanted mechanical valve prosthesis.\n* New York Heart Association Class IV congestive heart failure or left ventricular ejection fraction less than 30%.\n* Patient has left atrial/left atrial appendage thrombus screened by echocardiography\n* Platelet\\<100\\*109/L or hemoglobin\\<100g/L\n* Expected lifespan less than 1 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Shulin Wu, M.D. Ph.D.","role":"CONTACT","phone":"+8613902255336","email":"doctorwushulin@163.com"},{"name":"Xianhong Fang, M.D. Ph.D.","role":"CONTACT","phone":"862083827812","phoneExt":"10512","email":"fangxianhong2000@sina.com"}],"locations":[{"facility":"Beijing Anzhen Hospital","city":"Beijing","state":"Beijing","zip":"100029","country":"China","contacts":[{"name":"Changsheng Ma, M.D. Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Nanfang Hospital","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","contacts":[{"name":"Xiaobo Huang, M.D. Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The first Affiliated Hospital of Guangzhou medical University","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","contacts":[{"name":"Wei Wang, M.D.","role":"CONTACT"}],"geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The first affiliated hospital of Jinan university","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","contacts":[{"name":"Aidong Zhang, M.D. Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The First Affiliated Hospital of Sun Yat-sen University","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","contacts":[{"name":"Yugang Dong, M.D. Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The second Affiliated Hospital of Guangzhou medical University","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","contacts":[{"name":"Shiming Liu, M.D. Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Guangdong Cardiovascular Institute, Guangdong General Hospital","city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The Affiliated Hospital of Guangdong Medical College","city":"Zhanjiang","state":"Guangdong","zip":"524000","country":"China","contacts":[{"name":"Chan Chen, M.D. Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":21.28145,"lon":110.34271}},{"facility":"Wuhan Asia Heart Hospital","city":"Wuhan","state":"Hubei","zip":"430000","country":"China","contacts":[{"name":"Su Xi, M.D. Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":30.58333,"lon":114.26667}}]},"referencesModule":{"references":[{"pmid":"25399274","type":"BACKGROUND","citation":"Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D; PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014 Nov 19;312(19):1988-98. doi: 10.1001/jama.2014.15192. Erratum In: JAMA. 2015 Mar 10;313(10):1061."},{"pmid":"24998121","type":"BACKGROUND","citation":"Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029. Erratum In: J Am Coll Cardiol. 2014 Sep 16;64(11):1186."},{"pmid":"21830957","type":"BACKGROUND","citation":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"},{"id":"D000000925","term":"Anticoagulants"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M3934","name":"Anticoagulants","asFound":"Domains","relevance":"HIGH"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}